In the treatment of metastatic tumors and the efficient inhibition of their recurrence, tumor photodynamic therapy (PDT) and photothermal therapy (PTT) have made encouraging clinical advances. However, two significant challenges for phototherapy still exist: tumor targeting and dose-limiting toxicity. Herein, the targeted agent FA (folic acid), the NIR absorber rGO/IR820 (reduced graphene oxide/new indocyanine green), and the biocompatible MSN (mesoporous silica) are simply combined to create a multifunctional near infrared (NIR) nanotherapeutic platform (FA/rGO/MSN-IR820) for tumor-specific therapy. When FA/rGO/MSN-IR820 is administered to tumors, the environment of the tumor, which is acidic, causes it to break down. In addition, The FA target stimulates cellular uptake by precisely identifying folate receptors (FRs), which is followed by the release of IR820 in tumor tissues, enabling precise NIR-II-mediated PDT/PTT combo therapy. All results demonstrate that the constructed nanotherapeutic platform exhibites excellent therapeutic performance, indicating that our technology may potentially provide an outstanding strategy for tumor-targeted therapeutics.